A Phase I, Multicenter, Dose-Escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients With Advanced Solid Tumors Harboring FGFR Gene Alterations

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-1959

Related search